Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million
September 28 2017 - 4:35PM
Sharpens Focus on Innovative
ADAPTIR®
Bispecific Antibody Platform and
IXINITY®
Commercial Asset
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company
focused on developing novel immuno-oncology and hematology
therapeutics, today announced that it has completed the sale of
three of its marketed products (WinRho® SDF, HepaGam B®, and
VARIZIG®) to Saol Therapeutics for total consideration of up to
$74.5 million.
Under the terms of a purchase agreement between
the companies, Saol Therapeutics has acquired three hyperimmune
products previously marketed by Aptevo: WinRho SDF for
autoimmune platelet disorder and hemolytic disease of the newborn;
HepaGam B for the prevention of Hepatitis B following liver
transplantation and for treatment following hepatitis B exposure;
and VARIZIG for treatment following exposure to varicella zoster
virus for individuals with compromised immune
systems.
The transaction is valued at up to $74.5
million, including an upfront payment of $65 million ($3.25 million
of which was placed in an escrow account), and an additional
potential milestone payment of up to $7.5 million related to the
achievement of gross profit milestones. In addition, Aptevo
may receive up to $2 million related to the collection of certain
accounts receivable.
“The sale of our hyperimmune products is a
transformative event for Aptevo that positions us well for future
value creation by strengthening our financial position and
sharpening our focus on our most promising commercial and pipeline
assets,” said Marvin L. White, President and Chief Executive
Officer. “I am very excited about the future of Aptevo for
good reason. We are in the enviable position of having a commercial
product (IXINITY®) with growth potential; a robust, leading-edge
protein therapeutic platform technology (ADAPTIR™) targeting
immuno-oncology and autoimmune diseases; multiple novel bispecific
antibody candidates advancing in clinical and preclinical
development; and finally, a wholly-owned portfolio of assets with
the optionality to potentially generate value from these assets
through future corporate partnerships. I feel very good about
the hand we are holding, and the opportunities ahead for Aptevo and
our stockholders.”
“Our core technology – the ADAPTIR platform, is
among a new class of targeted, antibody-based therapeutics that
hold promise for the treatment of cancer and other chronic diseases
through the simultaneous targeting of two or more distinct
epitopes, activating and engaging the immune system to fight
cancer, or, in some cases, suppressing the immune response to
decrease inflammation. With bispecifics gaining increasing
momentum as a promising new class of “off-the-shelf” engineered
therapeutics, Aptevo is now better capitalized and positioned to
advance our bispecific pipeline and build value for our
stockholders. We are excited about the unique features of our
technology platform, and with second generation ADAPTIR candidates
heading towards the clinic, the opportunity to establish Aptevo as
a premier company focused on the next generation of
antibody-mediated therapeutics for the treatment of cancer and
autoimmune diseases,” concluded Mr. White.
Aptevo Portfolio: Commercial and
Investigational Products
- IXINITY® – an intravenous recombinant factor
IX therapeutic for use in people with Hemophilia B – a hereditary
bleeding disorder characterized by a deficiency of clotting factor
IX in the blood, which is necessary to control bleeding.
IXINITY was launched in 2015 and is marketed in the United States
by Aptevo.
- APVO414 – a bispecific ADAPTIR candidate,
currently in Phase 1 development, targeting prostate specific
membrane antigen (PSMA), an enzyme that is expressed on the surface
of prostate cancer cells, and, CD3, a component of the T cell
receptor complex expressed on all T cells. APVO414 redirects
T cells to specifically kill PSMA expressing tumors and is being
developed for metastatic castration-resistant prostate cancer,
which is advanced prostate cancer that has spread to other organs
and no longer responds to hormone blocking therapies.
- Otlertuzumab – a monospecific ADAPTIR
candidate currently in Phase 2 development for the treatment of
chronic lymphocytic leukemia (CLL). Data from a Phase 2
clinical trial evaluating otlertuzumab in combination with
bendamustine, compared to bendamustine alone, demonstrated a
significant increase in median progression free survival for the
combination, from approximately 10 to 16 months.
- APVO436 – a bispecific ADAPTIR candidate
currently in preclinical development targeting CD123, a cell
surface receptor highly expressed on several hematological
malignancies and CD3, a component of the T-cell receptor. APVO436
is designed to engage T cells to kill tumor cells.
- ALG.APV-527 – a bispecific antibody candidate,
partnered with Alligator Bioscience, featuring a novel mechanism of
action designed to simultaneously target 4-1BB (CD137) and an
undisclosed tumor antigen. 4-1BB, a costimulatory receptor on
T cells, is known to enhance the immune response to cancer through
activation of tumor-specific T cells and is believed to be a
promising target for new immunotherapeutic approaches. ALG.APV-527
could potentially have utility in the treatment of a broad spectrum
of cancers over-expressing the tumor antigen, including breast,
cervical, non-small-cell-lung, prostate, renal, gastric, colorectal
and bladder cancers.
- APVO210 – a bispecific ADAPTIR preclinical
candidate with a novel mechanism of action based on targeted
cytokine delivery. APVO210 is composed of a humanized
anti-CD86 antibody fused with a modified form of IL-10 that
specifically induces IL-10 signaling on antigen presenting cells,
but not on lymphoid populations. APVO210 functions by suppressing
immune responses and inducing certain tolerogenic responses and
therefore may have potential benefit for the treatment of
autoimmune and inflammatory diseases.
- ROR1 Bispecific – a proof-of-concept
bispecific candidate targeting ROR1, an antigen found on several
solid tumors and hematologic, or blood-related malignancies.
Initial preclinical data demonstrate redirected T cell killing of
tumors expressing ROR1 in vitro and in vivo in animal models.
Piper Jaffray & Co. served as exclusive
financial advisor to Aptevo for this transaction.
About Aptevo Therapeutics
Inc.
Aptevo Therapeutics Inc. is a clinical-stage
biotechnology company focused on novel oncology and hematology
therapeutics to meaningfully improve patients’ lives. Aptevo
has a commercial product, IXINITY®, approved and marketed in the
United States for the treatment of Hemophilia B, and a versatile
core technology – the ADAPTIR™ modular protein technology platform
capable of generating highly-differentiated bispecific antibodies
with unique mechanisms of action to treat cancer or autoimmune
diseases. Aptevo has two ADAPTIR antibody candidates
currently in clinical development and a broad pipeline of novel
investigational-stage bispecific antibody candidates focused in
immuno-oncology and autoimmune disease and inflammation. For more
information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements, other than statements of
historical fact, including, without limitation, statements
regarding potential milestone payments, Aptevo’s outlook, financial
performance or financial condition, Aptevo’s technology and related
pipeline, collaboration and partnership opportunities, commercial
portfolio, and any other statements containing the words
“believes,” “expects,” “anticipates,” “intends,” “plans,”
“forecasts,” “estimates,” “will” and similar expressions are
forward-looking statements. These forward-looking statements are
based on Aptevo’s current intentions, beliefs and expectations
regarding future events. Aptevo cannot guarantee that any
forward-looking statement will be accurate. Investors should
realize that if underlying assumptions prove inaccurate or unknown
risks or uncertainties materialize, actual results could differ
materially from Aptevo’s expectations. Investors are, therefore,
cautioned not to place undue reliance on any forward-looking
statement. Any forward-looking statement speaks only as of the date
of this press release, and, except as required by law, Aptevo does
not undertake to update any forward-looking statement to reflect
new information, events or circumstances.
There are a number of important factors that
could cause Aptevo’s actual results to differ materially from those
indicated by such forward-looking statements, including possible
negative effects on our business operations, assets or financial
results as a result of the closing of the transaction;; a
deterioration in Aptevo’s business or prospects; the parties may be
unable to achieve the anticipated benefits of the transaction;
adverse developments in the U.S. or global capital markets, credit
markets or economies generally; and changes in regulatory, social
and political conditions. Additional risks and factors that may
affect results are set forth in Aptevo’s filings with the
Securities and Exchange Commission, including its most recent
Annual Report on Form 10-K, as filed on March 31, 2017, and its
subsequent reports on Form 10-Q and current reports on Form 8-K.
The foregoing sets forth many, but not all, of the factors that
could cause actual results to differ from Aptevo’s expectations in
any forward-looking statement.
For Further Information:
Aptevo Therapeutics Stacey JurchisonSenior Director, Investor
Relations and Corporate Communications206-859-6628
JurchisonS@apvo.com
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Apr 2023 to Apr 2024